Fisher Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $25.6M | Sell |
127,994
-2,864
| -2% | -$567K | 0.01% | 303 |
|
|
2025
Q4 | $24.7M | Buy |
130,858
+21,932
| +20% | +$4.21M | 0.01% | 299 |
|
|
2025
Q3 | $19.3M | Buy |
108,926
+2,860
| +3% | +$425K | 0.01% | 328 |
|
|
2025
Q2 | $12.1M | Sell |
106,066
-1,440
| -1% | -$154K | ﹤0.01% | 386 |
|
|
2025
Q1 | $11.3M | Buy |
107,506
+6,868
| +7% | +$777K | ﹤0.01% | 396 |
|
|
2024
Q4 | $10.8M | Buy |
100,638
+41,064
| +69% | +$4.64M | ﹤0.01% | 422 |
|
|
2024
Q3 | $5.96M | Buy |
59,574
+6,555
| +12% | +$660K | ﹤0.01% | 471 |
|
|
2024
Q2 | $4.47M | Sell |
53,019
-358
| -0.7% | -$28.5K | ﹤0.01% | 497 |
|
|
2024
Q1 | $3.9M | Buy |
53,377
+4,080
| +8% | +$301K | ﹤0.01% | 521 |
|
|
2023
Q4 | $3.52M | Buy |
49,297
+16,035
| +48% | +$946K | ﹤0.01% | 529 |
|
|
2023
Q3 | $1.99M | Sell |
33,262
-2,563
| -7% | -$169K | ﹤0.01% | 632 |
|
|
2023
Q2 | $2.58M | Sell |
35,825
-4,075
| -10% | -$306K | ﹤0.01% | 623 |
|
|
2023
Q1 | $2.94M | Buy |
39,900
+242
| +0.6% | +$17.2K | ﹤0.01% | 606 |
|
|
2022
Q4 | $2.65M | Sell |
39,658
-5,691
| -13% | -$370K | ﹤0.01% | 605 |
|
|
2022
Q3 | $2.44M | Buy |
45,349
+33,437
| +281% | +$1.97M | ﹤0.01% | 546 |
|
|
2022
Q2 | $663K | Sell |
11,912
-64
| -0.5% | -$3.63K | ﹤0.01% | 673 |
|
|
2022
Q1 | $840K | Buy |
11,976
+64
| +0.5% | +$4.64K | ﹤0.01% | 645 |
|
|
2021
Q4 | $1.15M | Sell |
11,912
-5
| -0% | -$462 | ﹤0.01% | 621 |
|
|
2021
Q3 | $1.04M | Buy |
11,917
+1,909
| +19% | +$148K | ﹤0.01% | 613 |
|
|
2021
Q2 | $819K | Buy |
10,008
+361
| +4% | +$30K | ﹤0.01% | 645 |
|
|
2021
Q1 | $917K | Sell |
9,647
-98,471
| -91% | -$9.31M | ﹤0.01% | 627 |
|
|
2020
Q4 | $6.71M | Sell |
108,118
-4,084
| -4% | -$233K | 0.01% | 393 |
|
|
2020
Q3 | $6.67M | Sell |
112,202
-7,122
| -6% | -$486K | 0.01% | 372 |
|
|
2020
Q2 | $8.33M | Sell |
119,324
-6,265
| -5% | -$397K | 0.01% | 346 |
|
|
2020
Q1 | $5.7M | Sell |
125,589
-13,755
| -10% | -$780K | 0.01% | 343 |
|
|
2019
Q4 | $9.07M | Sell |
139,344
-18,067
| -11% | -$1.21M | 0.01% | 351 |
|
|
2019
Q3 | $9.78M | Buy |
157,411
+20,438
| +15% | +$1.28M | 0.01% | 362 |
|
|
2019
Q2 | $9.75M | Buy |
136,973
+21,948
| +19% | +$1.62M | 0.01% | 364 |
|
|
2019
Q1 | $9.02M | Buy |
115,025
+9,059
| +9% | +$686K | 0.01% | 365 |
|
|
2018
Q4 | $8.97M | Buy |
105,966
+37,648
| +55% | +$4.01M | 0.01% | 351 |
|
|
2018
Q3 | $11.7M | Sell |
68,318
-3,391
| -5% | -$511K | 0.01% | 331 |
|
|
2018
Q2 | $9.27M | Sell |
71,709
-3,501
| -5% | -$391K | 0.01% | 357 |
|
|
2018
Q1 | $7.75M | Sell |
75,210
-13,053
| -15% | -$1.29M | 0.01% | 367 |
|
|
2017
Q4 | $7.54M | Sell |
88,263
-2,074
| -2% | -$180K | 0.01% | 364 |
|
|
2017
Q3 | $7.67M | Sell |
90,337
-6,324
| -7% | -$501K | 0.01% | 347 |
|
|
2017
Q2 | $7.32M | Sell |
96,661
-144
| -0.1% | -$10.1K | 0.01% | 345 |
|
|
2017
Q1 | $6.39M | Sell |
96,805
-8,175
| -8% | -$538K | 0.01% | 330 |
|
|
2016
Q4 | $6.65M | Sell |
104,980
-11,061
| -10% | -$698K | 0.01% | 325 |
|
|
2016
Q3 | $7.39M | Hold |
116,041
| – | – | 0.01% | 320 |
|
|
2016
Q2 | $9.18M | Buy |
116,041
+2,896
| +3% | +$215K | 0.02% | 299 |
|
|
2016
Q1 | $8.79M | Hold |
113,145
| – | – | 0.02% | 300 |
|
|
2015
Q4 | $7.65M | Sell |
113,145
-160
| -0.1% | -$9.88K | 0.01% | 318 |
|
|
2015
Q3 | $6.05M | Sell |
113,305
-15,910
| -12% | -$965K | 0.01% | 323 |
|
|
2015
Q2 | $8.13M | Sell |
129,215
-2,084
| -2% | -$114K | 0.02% | 302 |
|
|
2015
Q1 | $6.32M | Hold |
131,299
| – | – | 0.01% | 322 |
|
|
2014
Q4 | $4.36M | Buy |
131,299
+74,780
| +132% | +$2.43M | 0.01% | 343 |
|
|
2014
Q3 | $1.66M | Sell |
56,519
-2,645
| -4% | -$87.8K | ﹤0.01% | 374 |
|
|
2014
Q2 | $2.3M | Buy |
+59,164
| New | +$2.4M | ﹤0.01% | 358 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Fisher Asset Management's LGND Position: Q1 2026 in Review
Fisher Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 2.2% in Q1 2026, selling an estimated $567K and leaving 127,994 shares worth $25.6M. The position accounts for 0.01% of the portfolio, ranked #303.
Fisher Asset Management first reported a position in LGND in Q2 2014 and has held it in 48 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Fisher Asset Management held 127,994 shares of Ligand Pharmaceuticals worth $25.6M as of Q1 2026.
- Fisher Asset Management sold 2,864 Ligand Pharmaceuticals shares in Q1 2026, an estimated $567K.
- Ligand Pharmaceuticals made up 0.01% of Fisher Asset Management's portfolio in Q1 2026, its #303 holding.
- Fisher Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.